From: Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?
Ref | Jadad score | Disorder | Meds | Age | Gen | Omega-3 fatty acid | Prep type | Duration | N | Outcome measure | Average baseline score | Δ | Statistical significant difference |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
66 | 5 | MDD | 100% | 50 | 81% | 1 g/day EPA | Ethyl ester | 12 weeks | 34 | HDRS | 20 | -3.8 | Yes |
 |  |  |  |  |  | 2 g/day EPA | Ethyl ester | 12 weeks | 35 | HDRS | 20 | +0.3 | No |
 |  |  |  |  |  | 4 g/day EPA | Ethyl ester | 12 weeks | 34 | HDRS | 19 | -0.3 | No |
68 | 3 | MDD | 100% | 53 | 85% | 2 g/day EPA | Ethyl ester | 4 weeks | 20 | HDRS | 22 | -10.8 | Yes |
69 | 4 | MDD | 100% | 38 | 80% | 2.2 g/day EPA 1.1 g/day DHA | Crude mixture | 8 weeks | 22 | HDRS | 22 | -7.2 | Yes |
71 | 4 | CD | 0% | 10 | 25% | 0.4 g/day EPA1 0.2 g/day DHA | Crude mixture | 16 weeks | 20 | CDRS | 69 | -25 | Yes |
74 | 2 | MDD | 0% | 47 | 80% | 2 g/day DHA | Crude mixture | 6 weeks | 35 | HDRS | 26 | -2.3 | No |
75 | 3 | MDD | 79% | 39 | 79% | 0.6 g/day EPA 2.4 g/day DHA | Crude mixture | 12 weeks | 77 | HDRS | 12 | +0.6 | No |
77 | 3 | BD | 100% | 43 | 66% | 6.2 g/day EPA 3.4 g/day DHA | Crude mixture | 4 months | 30 | YMRS | 7 | +1.3 | No |
 |  |  |  |  |  |  |  |  |  | HDRS | 11 | -7.7 | Yes |
80 | 5 | BD | 100% | 47 | 76% | 1 g/day EPA | Ethyl ester | 12 weeks | 50 | YMRS | 6 | -3.62 | No |
 |  |  |  |  |  |  |  |  |  | HDRS | 15 | -3.6 | No |
 |  |  |  |  |  | 2 g/day EPA | Ethyl ester | 12 weeks | 51 | YMRS | 5 | -12 | No |
 |  |  |  |  |  |  |  |  |  | HDRS | 15 | -3 | No |
 |  |  |  |  |  | 1 and 2 g/day groups combined | Ethyl ester | 12 weeks | 51 | YMRS | 6 | -2.32 | No |
 |  |  |  |  |  |  |  |  |  | HDRS | 15 | -3.3 | Yes |
81 | 5 | BD | 100% | 45 | 85% | 6 g/day EPA | Ethyl ester | 16 weeks | 116 | IDS | NS | -0.4 | No |
 |  |  |  |  |  |  |  |  |  | YMRS | NS | +0.6 | No |
86 | 5 | PPD | 0% | 31 | 100% | 0.2 g/day DHA | Crude mixture | 4 months | 89 | BDI | 7 | +0.4 | No |